FDA Achieves Unexpected Wins Against Unproven Stem Cell Clinics
Despite concerns after a health secretary disclosed personal stem-cell use abroad, the FDA has made notable regulatory progress against dubious clinics.
When the health secretary admitted on a podcast that he received experimental stem-cell treatments overseas, many feared a regulatory backslide for domestic clinics offering similar unproven services. Surprisingly, the Food and Drug Administration has delivered two major, evidence-driven interventions against such operators during the current administration. These successes stand out amid a climate of ideologically driven medical policy decisions.
Analysts note that more than 2,000 companies across the United States are believed to market unapproved cellular therapies. The FDA’s actions suggest a renewed emphasis on scientific standards despite broader political pressures. Observers view this as a bright spot in an otherwise contentious regulatory landscape.
Why it matters
Effective FDA action can protect patients from unsafe, unproven stem-cell treatments sold by thousands of clinics.
In this story
